Your browser doesn't support javascript.
loading
Genetic and Phenotypic Profiling of Triptan Users in a Swedish Cluster Headache Cohort.
Jennysdotter Olofsgård, Felicia; Ran, Caroline; Qin, Yuyan; Fourier, Carmen; Waldenlind, Elisabet; Steinberg, Anna; Sjöstrand, Christina; Belin, Andrea Carmine.
Afiliación
  • Jennysdotter Olofsgård F; Centre for Cluster Headache, Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Ran C; Centre for Cluster Headache, Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Qin Y; Centre for Cluster Headache, Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Fourier C; Centre for Cluster Headache, Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Waldenlind E; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Steinberg A; Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.
  • Sjöstrand C; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Belin AC; Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.
J Mol Neurosci ; 74(2): 45, 2024 Apr 18.
Article en En | MEDLINE | ID: mdl-38634984
ABSTRACT
Up to 25% of individuals who live with cluster headache (CH), an extremely painful primary headache disorder, do not adequately respond to the first-line treatment, triptans. Studies have indicated that genetic variants can play a role in treatment response. Likewise, differences in clinical characteristics can give clues to mechanisms underlying triptan non-response. Our aim was to investigate five genetic variants previously implicated in triptan response and their relation to triptan usage in our Swedish CH cohort and to investigate potential distinctions in clinical characteristics. 545 CH patients were screened for the genetic variants rs1024905, rs6724624, rs4795541, rs5443, and rs2651899 with a case control design based on triptan usage. Analysis of clinical characteristics was based on self-reported questionnaire data from 893 patients. One genetic variant, rs1024905, was significantly associated with triptan non-usage in CH (Pc = 0.010). In addition, multi-allele effector analysis showed that individuals with a higher number of effector variants were less likely to use triptans (P = 0.007). Analysis of clinical characteristics showed that triptan users were more likely to have alcohol as a trigger (57.4% vs 43.4%, P = 0.002), have autonomic symptoms (95.1% vs 88.1%, P = 0.002), and be current smokers (27.0% vs 21.9%, P = 0.033) compared to non-users. These results support the hypothesis that genetic variants can play a role in triptan usage in CH and that patients with a typical CH phenotype are more likely to use triptans.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Cefalalgia Histamínica Límite: Humans País/Región como asunto: Europa Idioma: En Revista: J Mol Neurosci Asunto de la revista: BIOLOGIA MOLECULAR / NEUROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Suecia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Cefalalgia Histamínica Límite: Humans País/Región como asunto: Europa Idioma: En Revista: J Mol Neurosci Asunto de la revista: BIOLOGIA MOLECULAR / NEUROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Suecia